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Washington University School of Medicine, St. Louis, MissouriABSTRACT Inference of the insulin secretion rate (ISR) from C-peptide measurements as a quantification of pancreatic b-cell
function is clinically important in diseases related to reduced insulin sensitivity and insulin action. ISR derived from C-peptide
concentration is an example of nonparametric Bayesian model selection where a proposed ISR time-course is considered to
be a ‘‘model’’. An inferred value of inaccessible continuous variables from discrete observable data is often problematic in biology
and medicine, because it is a priori unclear how robust the inference is to the deletion of data points, and a closely related ques-
tion, how much smoothness or continuity the data actually support. Predictions weighted by the posterior distribution can be cast
as functional integrals as used in statistical field theory. Functional integrals are generally difficult to evaluate, especially for
nonanalytic constraints such as positivity of the estimated parameters. We propose a computationally tractable method that
uses the exact solution of an associated likelihood function as a prior probability distribution for a Markov-chain Monte Carlo
evaluation of the posterior for the full model. As a concrete application of our method, we calculate the ISR from actual clinical
C-peptide measurements in human subjects with varying degrees of insulin sensitivity. Our method demonstrates the feasibility
of functional integral Bayesian model selection as a practical method for such data-driven inference, allowing the data to deter-
mine the smoothing timescale and the width of the prior probability distribution on the space of models. In particular, our model
comparison method determines the discrete time-step for interpolation of the unobservable continuous variable that is supported
by the data. Attempts to go to finer discrete time-steps lead to less likely models.INTRODUCTIONThe inference of continuous quantities from small numbers
of measurements is ubiquitous in medicine and biology.
Bayesian model comparison is ideally suited for such tasks
because it automatically invokes Occam’s principle and
balances goodness-of-fit against the complexity of the
model (1–3). However, Bayesian methods are computation-
ally intractable for high dimensional problems as they
require integration over the parameter space. Hence, many
theoretical advances in Bayesian inference (4) have not
yet been fully exploited in applications. Here we show
that such integrals become numerically tractable if a suitable
approximation of the prior probability distribution can be
explicitly calculated to provide an initial condition for
a Markov-chain Monte Carlo (MCMC) evaluation of the
model posterior probabilities (i.e., Bayes factors). MCMC
will generally not converge to a meaningful result unless
a good initial condition is specified. For concreteness, we
present the application of this general methodology to
a concrete example of clinical relevance with data from
human subjects in this article.Submitted August 19, 2011, and accepted for publication December 23,
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0006-3495/12/02/0399/8 $2.00The accurate determination of pancreatic b-cell function
as manifested in the insulin secretion rate (ISR) is clinically
important in assessing the contribution of abnormal insulin
secretion to diseases related to reduced insulin sensitivity
and insulin action such as prediabetes and diabetes mellitus
(5,6). The extraction of insulin secreted into the portal vein
by the liver precludes the direct measurement of the ISR
from peripherally sampled insulin concentration (7,8).
C-peptide is cosecreted in an equimolar amount with insulin
by pancreatic b-cells and the concentration is negligibly
affected by first-pass hepatic metabolism (9). The ISR is
then equivalent to the C-peptide secretion rate, which can
be found from the plasma C-peptide time-course and the
C-peptide clearance rate. The relationship between
C-peptide and insulin can be quantified using a two-
compartment model of plasma and extravascular C-peptide
allowing for the inference of ISR by solving an inverse
problem. C-peptide clearance by the kidneys is dependent
on the ISR per se and changes in C-peptide clearance are
not measurable in the urine (10). We concentrate on the
two-compartment model, leaving refinements to account
for kidney function for future work. Thus, for our purposes,
the problem comes in attempting to infer the continuous
secretion rate from incomplete discretized C-peptide
measurements.
The traditional method of solving this inverse problem is
to either reduce the dimensionality by using a parametricdoi: 10.1016/j.bpj.2011.12.046
400 Heuett et al.form for the ISR or use some interpolation method to infer
the missing data. A major problem with this approach is
that the formula for inferring the ISR from the discrete
C-peptide measurements involves the numerical differenti-
ation of an interpolated C-peptide time-course. As is well
known, the numerical derivative of an interpolated function
depends sensitively on the interpolation. Thus, these
methods are ad hoc in the sense that the constraints are
imposed extemporaneously to the data and it is unclear
how much smoothness or continuity the data actually
support. A more suitable situation is to let the data,
combined with the minimal desideratum for the ISR
(namely, continuity of the secretion profile), predict the
missing data. Bayesian model comparison is a principled
means of predicting data at unsampled time points because
it balances the complexity of the model with goodness-
of-fit to the experimental data. On the other hand, it also
requires integration over high-dimensional spaces that is
usually neither analytically nor numerically tractable. We
take a two-step strategy where we consider a reduced
problem that can be analytically solved and then use this
solution as a starting point for a numerical MCMC
integration.
ISR quantitative models have been considered exten-
sively in the literature. The secretion and disposition charac-
teristics of C-peptide are incorporated into a model, as
proposed by Eaton et al. (11) (Fig. 1). Plasma C-peptide
and extravascular C-peptide concentrations vary according
to a two-compartment model with dynamics obeying
dC
dt
¼ ðk1 þ k3ÞCþ k2Y þ SðtÞ; (1)
dYdt
¼ k1C k2Y; (2)
where C is the plasma C-peptide concentration, Y is the
extravascular C-peptide concentration, and S(t) is the rate
of production of C-peptide, i.e., the secretion rate from
the pancreas to be inferred. The kinetic parameters k1, k2,
and k3 could be calculated on an individual basis byFIGURE 1 C is the intravascular C-peptide concentration, Y is the extra-
vascular concentration, and S is the ISR. The rate constants (k1, k2, and k3)
are determined individually according to the procedure developed by Van
Cauter et al. (12).
Biophysical Journal 102(3) 399–406measuring the rate of disappearance of injected C-peptide
from the plasma (11), but such data are not always avail-
able. However, it is possible to rely on standard parameters
calculated from individual clinical characteristics following
Van Cauter et al. (12). This classic model does not account
for ISR-dependent renal uptake of C-peptide, but we post-
pone an actual change in the model structure for the future.
Our aim in this article is to present a methodology to obtain
the ISR function from Bayesian functional integrals
applied to this standard C-peptide model.
Equations 1 and 2 can be solved in closed form for the
secretion rate, S, in terms of a given C-peptide concentration
profile, C. This is the classic approach taken, and it yields
the theoretical solution





þ ðk1 þ k3ÞCðtÞ; (3)where C0 is the C-peptide concentration at the initial time,
t0 ¼ 0. In practice, the C-peptide concentration profiles
can only be measured discretely according to an experi-
mental protocol. Hence, an interpolation step is required
to estimate the integral and derivative in Eq. 3, and the
numerical derivative, in particular, depends on the interpola-
tion method used.
Our two-step approach to bypass numerical interpolation
is to perform a Bayesian functional integral over possible
ISR profiles S(t), weighted by requiring 1), consistency
with C-peptide data, and 2), continuity in the secretion
profile. Regarding S(t) as a model, the posterior probability
of S(t) is given by Bayes’ theorem,
P

SðtÞjdatafPdatajSðtÞPSðtÞ; (4)with P[data j S(t)] as the probability of the C-peptide data
arising from a particular S(t), and P[S(t)] as the a priori
probability of that S(t), giving a higher probability to
a smoother S(t). For our prediction, we take the expectation
value of S(t) over the posterior probability,
SðtÞpred ¼
Z
DSðtÞPSðtÞjdataSðtÞ; (5)where DSðtÞ P½SðtÞjdata is the measure for the functional
integral over all possible ISR functions S(t) We will assume
DS(t) to be the product (over the time points t) of the stan-
dard translation invariant Lebesgue measure for S(t). We
show how to compute this functional integral by using an
exact solution to an associated problem in the Methods.
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We implement the exact numerical problem as follows: Assuming the
C-peptide concentration is measured at discrete times t0, t1, ., tm, we
define the vector~c ¼ ðC1  C0;C2  C0;.;Cm  C0ÞT, where Ci denotes
the C-peptide measurement at time ti. Representing the differential system
in Eqs. 1 and 2 in matrix form, we solve for ~c ¼MK0~s, where
~s ¼ ðS1  S0; S2  S0;.; Sn  S0ÞT is the nonbasal secretion rate at n
evenly spaced time points from tm/n to tm. K
0 is an n  n lower-triangular
matrix with tm/2n along its main diagonal and with i
th row, jth column
entries, K
0






where l1 and l2 are the eigenvalues, with corresponding eigenvectors,
~v1 ¼ ðv11; v12ÞT and~v2 ¼ ðv21; v22ÞT, of the systemmatrix of the differential
system. Equation 6 employs the trapezoidal rule for numerical integration
(13). Thus, the integral is numerically evaluated as a sum of terms using
Zb
a
f ðxÞdx ¼ ðb aÞ ðf ðaÞ þ f ðbÞÞ
2
for each time step.M is an m  n matrix that is used to select the entries of
K0~s that coincide with the C-peptide measurements, i.e., the ith entry is
selected if tmi/n ˛ {t1, t2,., tm} because the experimental data we are using
only samples C-peptide values at specific time points.
In writing~c ¼MK0~s, we assume the discrete times chosen for the secre-
tion rate include all times, ti, for which C-peptide measurements are made.
If that is not the case,~c is simply redefined to exclude those entries that are
omitted by the scheme. To simplify notation, we define the m  n matrix
K ¼ MK0. We define a matrix, F, to perform numerical differentiation.
We use a three-point formula for differentiation (13). Thus, the derivative
matrix F is computing f0(x)¼ (f(xþ h) – f(x – h))/2 h. This solution provides
the nonbasal secretion rate. The total secretion rate, ~S, is equal to k3C0 at
time t0, because the system is assumed to be in equilibrium at that time,
and si þ k3C0 at each later time point, ti, in the discretization scheme. As
this is all linear algebra to this point, nothing prevents the predicted secre-
tion rate from having nonpositive values.
The measure for the functional integral, Eq. 5, may be written in the form
















The first term in E isln(P[data j S(t)]), and the remaining two terms corre-
spond to ln(P[S(t)]). We explain the meaning of each of these terms in
turn. K is the matrix representing the linear solution of Eqs. 1 and 2, giving
the C-peptide concentration as a function of~s. Thus, this term is a measure
of goodness of fit, measuring the deviation of the predicted C-peptide from
a given ISR model~s from the experimentally observed~c: The second term
measures continuity as F is a matrix representing the linear operation of
differentiation. Thus, this term is a constraint on the difference between
successive ~s values in a given ISR model, giving higher probability to ~s
values that are smoother. In particular, this term connects integrand vari-
ables in the product that measure DSðtÞ ¼ D~s; and implies that the values
in the ISR are not independent random variables. The last term enforces
the constraint that~s is nonnegative, according a vanishing probability to~s
with negative values at any time point. This is the term that renders an exact
Gaussian evaluation of the integral impossible, as it is not quadratic in~s.
The exact functional form of the last term in Eq. 7 does not affect the
results. The normalizations of these terms are dictated by experimentaluncertainties: the intrinsic fluctuations of the experimental data, ~sc, and
the fluctuations in the secretion rate, ~ss, propagated through the model
from the magnitude of the fluctuations observed in the experimental data
(details below). The magnitude of d is 105, which is well below the uncer-
tainty in experimental measurements for the data presented in this article.
The number of time points at which we evaluate~s is also a model param-
eter. In particular, it is determined by the discretization, and in the
following, we show that the appropriate step size, h, of the discretization
scheme chosen for~s, is also picked out by the Bayesian model selection.
The weighting factor, g, in Eq. 7 is the final model parameter in the set
that distinguishes different models, Xh,g, in the model comparison.
The functional integral in Eq. 5 would be impossible due to the large
number of variables in the integration. For example, for a time step of
h ¼ 0.5 min, there are ~240 values in the ISR time-course. However, we
are able to find the maximum of the measure exactly by neglecting the non-
negativity constraint in a preliminary calculation. In this preliminary calcu-
lation, we suppose that we want to solve~cK~s ¼ 0 exactly, because this is
just a matrix representation of the linear differential equations of the two-
compartment model (Eqs. 1 and 2). Because this is an underdetermined
system, we can also require that the solution minimizes kF~s2k, which is
exactly the second term in Eq. 7, favoring continuous secretion profiles.
This constrained linear algebra problem can be explicitly solved by
means of Lagrange multipliers, n, with an associated Hamiltonian function,
H ¼ 1
2
ð~s;FTF~sÞ þ ð~n; ð~cK~sÞÞ, which has minima where
vH
v~n
¼ ~cK~s ¼ ~0; (8)
vH T T T
v~s
¼ ~s F F~n K ¼ ~0: (9)
Now, it follows by multiplying the transpose of the second equation by
K(FTF)1 that
K~s ¼ KFTF1KT~n; (10)
but then
~c ¼ KFTF1KT~n: (11)
Solving for~n;
~n ¼ KFTF1KT1~c; (12)
and, therefore, multiplying both sides by (FTF)1 KT,
~s ¼ FTF1KTKFTF1KT1~c: (13)
Weminimize Eq. 7 and fit each model separately to data from each of the
subjects in our study. All the points of a secretion rate profile are varied
collectively in the optimization process using a Markov-chain Monte Carlo
method with parallel tempering (2). Optimizations are performed for each
model considered using 10 uniformly spaced values (100–1000) for the
tempering parameter, b, and the corresponding updating probability,
ebE. Simulations begin with an initial~S calculated from Eq. 13 with any
negative values replaced by 2d. After equilibration, 105 iterations are per-
formed for each tempering parameter, and statistics, such as h~Sib and
hEib, are calculated.
The probability distribution for the model conditional on the data, D, is
denoted as P(Xh,g j D). We calculate the log probability that the model
describes the data for each individual, i, asBiophysical Journal 102(3) 399–406





and across all individuals as
   X
ln P Xh;gDall subjects ¼
i
ln PðXh;gjDiÞ:
The model with the largest log-likelihood is chosen as the winning model
with optimal parameter values on a population basis. The advantage of
this method is that it balances goodness of fit, smoothness, and nonnegativ-
ity while fitting the models to the data from each individual separately, all
within the same numerical procedure. The method also removes the subjec-
tiveness of choosing how to interpolate the C-peptide profile and how to dis-
cretize the secretion rate.
We apply the improved model of the ISR to C-peptide data from hyper-
glycemic glucose clamp studies. Plasma concentrations were measured at
10, 5, 0, 2, 4, 6, 8, 10, 15, 20, 30, 40, 45, 47, 48, 50, 55, 60, 70, 75,
80, 85, 90, 100, 105, 110, and 120 min in 45 subjects (4 overweight and
41 obese, 4 normal glucose tolerance, 23 impaired glucose tolerance and
19 type-2 diabetes mellitus, 30 female and 15 male, and 31 black and 14
white). After a 12-h overnight fast, a hyperglycemic glucose clamp was
initiated with a 10-min priming infusion of 20% dextrose to raise plasma
glucose concentration to 13.9 mM. After the priming dose the infusion
rate was adjusted every 5 min to maintain plasma glucose concentration
at 13.9 mM. At 45 min after the start of the dextrose infusion, 5 g of arginine
monohydrochloride in 50 mL of normal saline was administered over 2 min
as a priming dose and a continuous infusion at 15 g/m2/h was given for the
remainder of the 2-h period. Seventy-five minutes after the start of the
dextrose infusion, subjects consumed a liquid fat drink (37.5 mL) contain-
ing 25 g of corn oil (Lipomul; Upjohn, Kalamazoo, MI). C-peptide
measurements were used to calculate the secretion rates over the
0–120 min time interval. For each individual, the ith component of ~sc
was calculated as Ci multiplied by the ratio of the standard deviation to
the mean of the 10, 5, and 0 min C-peptide measurements.
The model is implemented in MATLAB (The MathWorks, Natick, MA).RESULTS
Fig. 2 shows the mean C-peptide profile of actual clinical
data obtained from hyperglycemic clamp experiments on












FIGURE 2 Average C-peptide profile from 45 subjects (14–16). Glucose
was infused during the entire trial. Arginine infusion began at 45 min. A
liquid fat drink was administered at 75 min. (Error bars) Mean5 SE.
Biophysical Journal 102(3) 399–406and 75 min represent the times at which arginine administra-
tion commenced and a liquid fat drink was administered,
respectively. The theoretical solution in Eq. 3 depends sensi-
tively on the interpolation scheme one uses, as shown in
Fig. 3. Note the appearance of negative S(t) predictions in
Fig. 3 as the smoothness of the interpolation scheme
increases. Alternatively, these data can be immediately con-
verted to preliminary S(t) profiles (the mean of these profiles
is shown in Fig. 4) using linear algebra (see Methods) and
subject-dependent parameters calculated according to Van
Cauter et al. (12).
These preliminary profiles sometimes exhibit negative
values, which is an artifact of the linear algebraic exact solu-
tion of an underdetermined problem with the smoothness
constraint. Truncating negative values to an arbitrarily small
positive number and using these preliminary S(t) profiles as
starting values allow MCMC evaluation of the functional
integral, with rapid equilibration as shown in Fig. 5. The
Bayesian prior probability distribution is comprised of three
components: enforcing the goodness-of-fit in predicting the
observed C-peptide data, continuity of the deduced ISR
profile, and the positivity of the deduced ISR profile. As
evident in Fig. 6, the relative impact of these desiderata in
the equilibration process changes.
We evaluated a variety of models to ascertain the most
likely step size in the discrete functional integrals and for
the relative weighting of the different components of the
Bayesian prior probability distribution. Fig. 7 shows the
log-likelihood of models (Bayes factors) with different
weights accorded to smoothness versus goodness-of-fit, as
a function of step-size. The most likely model for this pop-
ulation of subjects has h ¼ 1 min and g ¼ 2. The subject
mean S(t) profile, deduced from the individual Bayesian
prior probability distribution-weighted mean S(t) profiles
over MCMC simulations, is shown in Fig. 8. As is evident,FIGURE 3 C-peptide profile referred to in Fig. 2 was interpolated using
a piecewise linear interpolation (interp1), a piecewise cubic Hermite inter-
polating polynomial (pchip), and a cubic spline interpolation (spline), each
with a step size of 1 min. ISR profile prediction calculated using Eq. 3 for
each individual and then averaged to yield the curves shown here. (Error
bars) Mean5 SE.
FIGURE 4 ISR profile prediction calculated using Eq. 13 for the
C-peptide profile data referred to in Fig. 2. ISR profiles were calculated






















FIGURE 6 Example of the individual cost components, i.e., cost associ-
ated with nonnegativity, smoothness, and goodness-of-fit, during an MCMC
simulation. The results shown are the components that sum together to yield
the total cost shown in Fig. 5.
Bayesian Functional Integral Method 403the predicted S(t) is not as smooth as the exact solution, but
is positive at all values. Fig. 9 illustrates the C-peptide
profiles that would be predicted from the S(t) profiles in
Figs. 3 and 8 according to the two-compartment model.
We note the physiologically incorrect prescient increase
in the S(t) profile before the 45-min mark in Fig. 8. The
increase is a result of the smoothness constraint being
applied across the physically discontinuous situation
involving the externally infused arginine. To account for
such experimental conditions, we must use all the infor-
mation available about the experiment, and impose
a discontinuity by considering the time intervals separately
and calculating the S(t) profiles sequentially, using the final
time point from one interval as the initial condition in the
next. Figs. 10 and 11 illustrate the S(t) profiles and corre-
sponding C-peptide profile predictions, respectively, for














FIGURE 5 Example of the total cost equilibrating during an MCMC
simulation. Total cost is calculated using Eq. 7, with h ¼ 1 and g ¼ 2,
and the initial ISR profile is calculated using Eq. 13. C-peptide data from
Subject 2 was used for this example.DISCUSSION
It is well established that insulin secretion is a pulsatile
process (17). When data points are sparse, methods that
use interpolation and Eq. 3 to estimate secretion rates tend
to flatten the secretion profile, or result in large value
changes, evident in Fig. 3. In contrast, our method shows
oscillatory behavior consistent with sparse data points, but
no artificial flattening of the secretion profile (Fig. 8).
Unfortunately, we have no data on the ‘‘ground’’ truth for
the insulin secretion rate. Such data would require a portal
vein catheterization to directly compare insulin secretion
with the C-peptide based indirect measurement. This is
a major invasive clinical procedure, and it would be uneth-
ical to ask healthy humans to undergo such an invasive
procedure without medical necessity. Thus we cannot stateFIGURE 7 A comparison of the log-likelihoods of the 12 models tested,
corresponding to all combinations of g ¼ 0.5, 1, 2, and h ¼ 0.5, 1, 2, 4.
From this it is determined that the model with h¼1 and g¼ 2 is the optimal
model on a population basis.
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FIGURE 8 MCMC simulations were performed for each of the 45
subjects, with h ¼ 1 and g ¼ 2, and the resulting average ISR profiles
were themselves averaged to yield the final result shown. The preliminary
model prediction from Fig. 4 is also shown for comparison. (Error bars)
Mean5 SE.
FIGURE 10 ISR profile predictions calculated using Eq. 3 for a variety of
interpolation methods (interp1, pchip, and spline) as well as Eq. 13 (our
model) for the first 40 min of C-peptide profile data referred to in Fig. 2.
Results were calculated for each individual and then averaged to yield
the curves shown here. (Error bars) Mean5 SE.
404 Heuett et al.definitively that our method gives results that are closer to
biological reality.
However, the 45 clinical subjects were categorized by
their glucose tolerance into three groups—normal glucose
tolerance (NGT), impaired glucose tolerance (IGT), and
type 2 diabetics (T2DM). As expected, these three groups
exhibit major differences in their ISR profiles (see
Fig. 12). The only model that shows physiologically real-
istic behavior in the computed ISR is our model. The Her-
mite interpolation and spline show a decrease in the ISR
in NGT subjects at the beginning of glucose infusion,
whereas the linear interpolation shows a slower initial rise
for NGT compared to IGT and T2DM. The spline interpola-
tion gives negative ISR values at the beginning and ~28 min
for NGT subjects. The sensitivity of the other models to data






















FIGURE 9 Average predicted C-peptide profiles from 45 subjects ac-
cording to the two-compartment model and using the classic ISR profile
predictions shown in Fig. 3 and the new ISR profile prediction shown in
Fig. 8. Results were calculated for each individual and then averaged to
yield the curves shown here. (Error bars) Mean5 SE.
Biophysical Journal 102(3) 399–4065 min. Thus our model is a qualitative and quantitative
improvement in the computation of a physiologically real-
istic ISR.
Combining parallel tempering for model comparison and
our functional integral evaluation, we can determine the
optimal step size, h, and the optimal weight for the prior
probability distribution on the space of function ‘‘models’’,
g, as in Fig. 7, in an entirely data-driven manner. This is
a simple way to avoid overfitting the data and taking bio-
logic variation into account. More detailed or more precise
data can be used in an incremental manner to continue
refining the choice of optimal parameters, a major factor
in favor of Bayesian approaches. The methodology used
here illustrates the practicality of using functional tech-
niques in biological applications, given the availability of


















FIGURE 11 Average predicted C-peptide profiles from 45 subjects
according to the two-compartment model using the classic and new ISR
profile predictions shown in Fig. 10. Results were calculated for each
individual and then averaged to yield the curves shown here. (Error bars)
Mean5 SE.
FIGURE 12 Average predicted C-peptide profiles from 45 subjects separated into normal glucose tolerance (NGT, bold line), impaired glucose tolerance
(IGT, regular line), and type 2 diabetes (T2DM, dotted line) for the four models.
Bayesian Functional Integral Method 405available for speeding up the numerical evaluation of the
MCMC sampling, such as using a nontrivial Hastings factor
or level-set representations. For our relatively small clinical
sample of subjects, this was not necessary. The biases
inherent in making choices to avoid underfitting or over-
modeling can be partially avoided by being more inclusive
in model evaluation, letting the available data set determine
the most likely model. Moreover, such detailed results may
show biological variability, evident in Fig. 8, which is more
realistic than idealizations.
We initially attempted to address this problem by means
of Gaussian process models, with continuous function deter-
mination without a discretization step. In our case, although
the linear algebra readily admits an h/ 0 limit, the next
step of evaluating the functional integral in the continuous
case with the positivity constraint in place is not tractable.
We therefore presented here the discrete analog of Gaussian
process models. As is standard in Gaussian process models,
a length scale is determined by Bayesian model comparison.
In our case, that length scale is the discretization scale h sup-
ported by the data. From the clinical data uncertainties
evident in the ISR computations, it is clear the discretization
in our approach is not the limiting factor in the accuracy of
the ISR (see Fig. 12).
We have emphasized that our method gives us limits on
how well one can expect to infer the unobserved variablefrom discrete constraints, because the optimal discretization
time step h is also determined by Bayesian model selection.
We use linear interpolation for values of the ISR between
these time steps, but the important point is that one could
use any interpolation as long as one keeps in mind that
any such interpolation is not constrained by the data. In
other words, the observations only determine differences
in ISR values for time points that are farther apart than h.
The ISR that we find is not smooth compared to splines or
interpolation. It is, however, taking into account biologic
fluctuations in the data for each individual subject.
Assuming that the ground truth secretion rate is smooth is
not justified by clinical experience for most hormones for
which such a comparison is practical.
The applicability of this methodology is more general
than the linear problem utilized in the example of the ISR
explicated here. Indeed, our method is applicable to
nonlinear problems with the following characteristics:
Experimental data at discrete time points,C(ti) as a constraint
on a continuous unobserved variable, S(t) that determines the
dynamics of C(t) by a general functional F [C(t), S(t)] ¼ 0.
Interpolating the experimental data to a function ~CðtÞ; we
can linearize the functional dependence as
F
h
~CðtÞ þ dCðtÞ; ~SðtÞ þ dSðtÞ
i
¼ 0: (14)Biophysical Journal 102(3) 399–406
406 Heuett et al.Expanding in powers of dC and dS after approximately
solving for ~SðtÞ in terms of the given function ~CðtÞ; we
arrive again at an underdetermined linear problem to which









dSðtÞ ¼ 0; (15)
with the appearance of the inhomogeneous first term due to
the fact that we do not require an exact solution of
F½~CðtÞ; ~SðtÞ ¼ 0: Because Eq. 15 is again a linear problem,
a smoothness-maximizing solution to the underdetermined
problem is easily found (see Methods). The smoothness
maximization is applied to ~Sþ dS; of course, but the method
remains applicable with trivial algebraic changes. Iteration
to improve choices of ~CðtÞ and ~SðtÞ used as starting points
is also possible.
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